GSK Investors Encouraged to Participate in Class Action Lawsuit

Investors in GSK plc (“GSK”) are being advised by The Portnoy Law Firm regarding the opportunity to join a class action lawsuit specifically for those who purchased company securities from February 5, 2020, to August 14, 2022. This legal action comes at no cost to investors seeking to recover potential losses linked to the company’s alleged misconduct.

Deadlines and Legal Options

Those interested in participating in this class action must submit a lead plaintiff motion by April 7, 2025. Investors are encouraged to connect with attorney Lesley F. Portnoy via phone at 310-692-8883 or email at le****@********aw.com. A complimentary case evaluation will be offered to discuss possible avenues for recovering losses.

Background on GSK and Allegations

GSK operates in the pharmaceutical sector, focusing on the research, development, and manufacturing of vaccines and medications. Central to the lawsuit is Zantac, a medication used to treat heartburn and acid reflux that has allegedly been associated with significant health risks. Historical data indicates that since its development, Zantac has generated billions in revenue for GSK and its predecessor company, Glaxo.

Key Allegations presented in the Lawsuit

The complaint against GSK suggests that the company was aware of the potential dangers of NDMA (N-nitrosodimethylamine), a harmful compound produced by Zantac, for nearly 40 years before it voluntarily withdrew the product from the market. Specific allegations include:

• GSK failed to disclose their knowledge of NDMA’s origins and its carcinogenic implications.
• Unpublished data linking Zantac usage to cancer was allegedly withheld from the public and investors.

Market Impact and Financial Implications

On August 10, 2022, a Deutsche Bank report raised alarms about potential liabilities faced by GSK and other Zantac distributors, projecting a financial exposure ranging from $5 billion to $10 billion. This announcement triggered a significant decline in GSK’s American Depository Receipts (ADRs), which dropped more than 10%. The following day, GSK acknowledged it might provide guidance on its potential liabilities, estimating a range between $1 billion and $10 billion, which led to an additional 3% drop in ADRs.

Next Steps for Interested Investors

For those looking to learn more about their rights and the possibility of joining the class action lawsuit, they are advised to visit The Portnoy Law Firm’s website to review detailed information and submit their transaction data.

About The Portnoy Law Firm

With a track record of recovering over $5.5 billion for investors negatively impacted by corporate misconduct, The Portnoy Law Firm focuses on holding companies accountable for their actions. Investor inquiries are confidential and will be handled with utmost professionalism by Lesley F. Portnoy, Esq., licensed in both California and New York.

Contact Information

You can reach Lesley F. Portnoy at:

• Email: le****@********aw.com
• Phone: 310-692-8883
• Website: www.portnoylaw.com

Attorney advertising. Prior results do not guarantee similar outcomes.